tetano
Editor, Senior Moderator
Expert Rev Vaccines. 2014 Jul 12:1-11. [Epub ahead of print]
Considerations for the rapid deployment of vaccines against H7N9 influenza.
Chua BY1, Brown LE, Jackson DC.
Author information
Abstract
The threat of an outbreak of avian-origin influenza H7N9 and the devastating consequences that a pandemic could have on global population health and economies has mobilized programs of constant surveillance and the implementation of preemptive plans. Central to these plans is the production of prepandemic vaccines that can be rapidly deployed to minimize disease severity and deaths resulting from such an occurrence. In this article, we review current H7N9 vaccine strategies in place and the available technologies and options that can help accelerate vaccine production and increase dose-sparing capabilities to provide enough vaccines to cover the population. We also present possible means of reducing disease impact during the critical period after an outbreak occurs before a strain matched vaccine becomes available and consider the use of existing stockpiles and seed strains of phylogenetically related subtypes, alternate vaccination regimes and vaccine forms that induce cross-reactive immunity.
KEYWORDS:
H7N9; adjuvant; influenza; pandemic; vaccine
PMID:
25017993
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25017993
Considerations for the rapid deployment of vaccines against H7N9 influenza.
Chua BY1, Brown LE, Jackson DC.
Author information
Abstract
The threat of an outbreak of avian-origin influenza H7N9 and the devastating consequences that a pandemic could have on global population health and economies has mobilized programs of constant surveillance and the implementation of preemptive plans. Central to these plans is the production of prepandemic vaccines that can be rapidly deployed to minimize disease severity and deaths resulting from such an occurrence. In this article, we review current H7N9 vaccine strategies in place and the available technologies and options that can help accelerate vaccine production and increase dose-sparing capabilities to provide enough vaccines to cover the population. We also present possible means of reducing disease impact during the critical period after an outbreak occurs before a strain matched vaccine becomes available and consider the use of existing stockpiles and seed strains of phylogenetically related subtypes, alternate vaccination regimes and vaccine forms that induce cross-reactive immunity.
KEYWORDS:
H7N9; adjuvant; influenza; pandemic; vaccine
PMID:
25017993
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25017993